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ABSTRACT 
Background: Portal vein occlusion (PVO) and associating liver partition and portal vein 
ligation for staged hepatectomy (ALPPS) are two strategies employed to render patients with 
unresectable liver tumours resectable by increasing the size of the future liver remnant (FLR). 
There is still limited knowledge about several aspects of PVO and most aspects of ALPPS. 
Aims: To evaluate tumour progression after portal vein embolization (PVE) in patients with 
colorectal liver metastases (CRLM) treated with pre-procedural chemotherapy. To investigate if 
ALPPS performed after failed PVO in patients with CRLM treated with neoadjuvant 
chemotherapy is safe and feasible. To assess and compare liver volume and function in patients 
subjected to ALPPS. To study the levels of liver regenerative growth factors in ALPPS. 
Methods: In paper I, patients with CRLM and response to neoadjuvant chemotherapy, 
subjected to PVE at Skåne University Hospital (2005-2013) and Karolinska University Hospital 
(2004-2010) were included in the study and assessed for tumour progression. In paper II, 
patients subjected to ALPPS after failed PVO at Karolinska University Hospital were included 
and efficacy and safety of the procedure in these patients was evaluated. In paper III, the liver 
volume and function in patients subjected to ALPPS was studied with a multimodal approach 
(including repeated computed tomography and hepatobiliary scintigraphy). In paper IV, 
sequentially sampled tissue from patients operated with ALPPS was analysed to assess the 
levels of liver regenerative growth factors. 
Results: In paper I, 34 patients were identified and included. The median time between ended 
chemotherapy and PVE was 16 days. Three patients had tumour progression in the embolized 
liver lobe and three in the non-embolized lobe. Only two patients experienced tumour 
progression in the FLR that inhibited curative resection. In paper II, eleven patients operated 
with ALPPS after failed PVO were included. Six days after stage 1 the median growth of the 
FLR was 61.8% and all patients could proceed to stage 2 and resection of the liver tumours on 
day 7, with low morbidity and no 90-day mortality. In paper III, nine patients were studied and 
the increase in FLR-volume exceeded the increase in FLR-function at day 6 after stage 1, where 
functional increase only reached 50% of the volume increase in the FLR. In paper IV, ten 
patients were studied. The levels of HGF in plasma correlated with the degree of growth of the 
FLR and the levels of IL-6 correlated with the HGF levels. 
Conclusions: The rate of progression of CRLM after PVE with pre-procedural chemotherapy is 
lower than previously reported if the time between the end of chemotherapy and PVE is short. 
The powerful growth of the FLR associated with ALPPS seems to be maintained in patients 
with CRLM treated with neoadjuvant chemotherapy and previously failed PVO. In the inter-
stage period of ALPPS the high volume increase is not paralleled by a corresponding functional 
increase. The levels of HGF in plasma correlates with the degree of growth of the FLR and the 
levels of IL-6 correlates with the HGF levels in patients operated with ALPPS. 
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1 INTRODUCTION 
Despite recent advances in both chemotherapy and ablation therapy, surgical resection 
remains as the gold standard for curative treatment of liver tumours [1, 2]. The development 
in liver surgery has been impressive during the last two decades which is attributed to several 
factors, such as improved surgical technique, optimized anaesthesia, modern chemotherapy 
drugs, refined radiology and methods for inducing preoperative growth of the healthy part of 
the liver [3]. One important feature, emanating from patients with colorectal liver metastases 
(CRLM), is a paradigm shift in assessing resectability. Where the old paradigm focused on 
mainly tumour related factors [4], the new paradigm instead defines resectability focusing on 
achieving radical resection with an adequate volume of the remaining liver (future liver 
remnant: FLR). Today the main restriction for curative liver resections is when the FLR is too 
small to sustain postoperative liver function during the regenerative process, as post-
hepatectomy liver failure (PHLF) still is the main reason for mortality after liver surgery [5-
9]. Therefore, together with the mentioned paradigm shift, there has been an increasing 
interest in developing different techniques that induce growth of the FLR, such as selective 
portal vein occlusion (PVO) by embolization (PVE) or ligation (PVL), two-stage 
hepatectomy (TSH) and more recently a new method called associating liver partition and 
portal vein ligation for staged hepatectomy (ALPPS) [10-12]. These techniques aim at 
converting irresectable patients due to small FLR to candidates for resection by achieving 
sufficient growth of the FLR, thus to allow curative liver surgery without unacceptable risk of 
PHLF. While small FLR volumes correlates with risk for PHLF there is still a need for 
methods to evaluate liver function more accurately than with just volume measurement [13]. 
This has resulted in an increased interest in studying both liver regeneration and liver function 
in relation to these techniques and liver resection [14-18]. 
In summary there is only low-grade evidence for several topics in this field. The main reason 
is that these procedures have been applied to a limited number of patients without consistent 
definitions, making comparisons of studies difficult. The aim of the performed studies of this 
doctoral project is to contribute to the understanding of some key concepts regarding PVO 
and ALPPS. 
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2 BACKGROUND 
2.1 FUTURE LIVER REMNANT 
2.1.1 Partial hepatectomy as a model to study liver regeneration 
Our knowledge of liver regeneration after partial hepatectomy is mainly derived from 
experimental models in rodents [19]. The most used model still consists of a 70 percentage 
hepatic resection in rats, developed by Higgins and Anderson already in 1931, and is one of 
the most studied models of tissue regeneration. As a result the understanding of the process of 
liver regeneration after partial hepatectomy has increased during the last decades. The role of 
certain cytokines and growth factors, such as interleukin 6, tumour necrosis factor-alpha, 
hepatocyte growth factor, epidermal growth factor, have been well characterized in corre-
sponding experimental settings [20]. In humans there are studies investigating liver 
regeneration, mainly in healthy individuals undergoing living donor liver transplantation [21, 
22]. In a study by Marcos et al [23] both donor and recipient in living donor liver 
transplantation were studied, and most of the regeneration in both the recipient and the donor 
occurred during the first week after resection or transplantation. However, most of the 
patients subjected to partial hepatectomy do not have healthy livers due to several causes 
(chemotherapy prior to surgery, cirrhosis, steatosis, cholestasis, among others) [2]. There 
have been sporadic reports on analysis of growth factors in patients with CRLM operated 
with partial hepatectomy [24], but little is known about how the temporal changes in growth 
factors are manifested before and after both stages of ALPPS. Again, our current knowledge 
of these potential mechanisms is based on some animal models [25, 26] and few on studies in 
humans [27, 28]. 
2.1.2 Posthepatectomy liver failure 
PHLF is one of the most feared complications after liver surgery and is associated with 
substantial morbidity and mortality [29, 30]. It is suggested that PHLF is the direct, or 
contributing, cause behind the majority of fatalities after liver resection [30]. There is a large 
variability in the reported incidence of PHLF in the literature, mainly due to a lack of a 
uniform definition of this condition [31]. Currently there are three dominating criteria for 
defining and predicting PHLF: the ’50-50 Criteria’ [5], the ISGLS Definition [8] and the peak 
bilirubin > 7 [32]. This contributes to the many difficulties in comparing PHLF between 
different studies. The mechanisms involved in PHLF are known to be multifactorial and 
several risk factors have been identified. These risk factors can be divided into three 
categories: patient comorbidity, background liver disease and surgery related factors [31]. For 
patient related factors age [5], diabetes mellitus [33] and obesity [34] are associated with 
increased risk for postoperative mortality associated with PHLF. Liver related factors such as 
chemotherapy-associated liver injury [35, 36], cirrhosis [37, 38] and cholestasis [39, 40] are 
probably the most important conditions that can influence postoperative regeneration and 
contribute to increased risk for PHLF. 
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Since there still are no reliable regional liver function tests (in order to accurately assess 
preoperative function of the FLR), measured volume of the FLR together with the estimated 
quality of the background liver tissue is central for preoperative decision-making when 
assessing resectability in order to avoid PHLF [41]. To this date there is no effective way to 
treat PHLF once it has occurred, and the quandary hepatobiliary surgeons are faced with is 
the pursuit to offer an increased amount of patients a curative resection without a rise in 
potentially fatal PHLF. 
2.1.3 Volume assessment of the future liver remnant 
FLR can be evaluated volumetrically in several ways. The original method consists in 
radiological measurement of the FLR volume and total liver volume (TLV) without tumours 
by subtracting tumour volume (TV), to obtain a total functional liver volume (TFLV) [42-
44]. The FLR volume (also with exclusion of eventual tumours) is then divided by the TFLV 
and multiplied with 100. This provides a percentage on how large portion of the total liver is 
represented by the FLR, and the formula for calculating FLR% = FLR / TFLV *100. This 
method requires an extensive and sometimes complicated volumetric measurement which is 
the rationale behind the development of the subsequent methods for evaluating the size of the 
FLR. 
Another method, originating from the living donor liver transplantation setting [45, 46], is to 
relate the volume of the FLR to body weight (BW) [47]. Since body weight correlates well 
with the weight of the liver [48], and ml/cm
3
 from the radiological measurements correlates 
with the weight of the liver in mg, body weight in mg can be translated to ml according to the 
formula: FLR/BW% = FLR / BW (kg x 1000) *100. 
A third, more recent, method uses a formula to calculate the total estimated liver volume 
(TELV) with body surface area (BSA) and is based on autopsy studies (TELV = -794 + 1276 
x BSA) [48-50]. This can then be used to calculate a standardized FLR (sFLR), also 
expressed as percentage, by the formula sFLR% = FLR / TELV *100. 
There is currently no consensus on which method that should be used, causing difficulties in 
interpreting results from different studies involving evaluation of the FLR [51-53]. In 
addition, there is no consensus on the required size of the FLR that should be obtained in 
order to avoid PHLF. Traditionally a FLR of 30% or more was considered sufficient for safe 
resection [54]. Currently, when evaluating the FLR before resection for CRLM there is a 
variety in recommended threshold levels, but most consider a FLR between 25-30% to be 
sufficient if previous chemotherapy have been administered to the patient [55, 56]. In patients 
with perihilar cholangiocarcinoma or hepatocellular cancer generally a larger FLR is 
considered to be necessary for safe resection due to a more impaired function of the native 
liver, but also here the variability applied complicates adequate comparison [57-59]. Also 
when FLR/BW is used there is a similar situation with different levels (between 0.4-0.8% for 
CRLM) being used for deciding on resectability [47, 51]. 
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2.1.4 Function assessment of the future liver remnant 
Several attempts to characterize FLR function instead of mere volume have been presented 
[60-66]. These consist mainly of biochemical parameters, ICG clearance test, hepatobiliary 
scintigraphy (HBS) and dynamic MRI. ICG clearance test is an established method to 
evaluate global liver function and is mainly used for preoperative assessment of liver function 
[43, 57, 67, 68]. However, it lacks the capacity to characterize regional function within the 
liver. Studies on HBS after PVE have shown that FLR function precede the volume increase 
after PVE [69, 70]. In this context it should be mentioned that HBS might even be more 
reliable than volume-based data in predicting PHLF [71], and a cut-off value for safe 
resection based only on HBS has been suggested [72].  
Still, volumetric evaluation of the FLR together with consideration for patient factors and 
assumed quality of the background liver, remain as largely dominating. 
 
2.2 PORTAL VEIN OCCLUSION 
PVO consists of a selective occlusion of the portal vein to the tumour bearing part of the 
liver, diverting all portal blood to the FLR in order to induce hypertrophy of this part. This 
can be achieved by both PVE and PVL, and the effect is then evaluated with radiological 
volume analysis, generally with contrast enhanced four-phase computed tomography (CE-
CT) [73-78]. There are several controversies regarding PVO. 
(i) PVE vs. PVL 
There are no randomized controlled studies comparing PVE to PVL. The main reason for this 
is that when you have a tumour-free FLR the option to perform a less invasive PVE at the 
angiography suite will make most liver surgeons reluctant to even consider PVL in these 
patients. While on the other hand many centres prefer PVL, instead of PVE, as part of an 
operation to clear the FLR from tumour prior to a second operation (i.e. TSH). A recent meta-
analysis states that there is no evidence of an obvious advantage of one technique over the 
other [79], although one has to bear in mind that all nine studies included in that meta-
analysis where small case series with heterogeneous design in terms of for example PVO 
technique, patient cohorts and waiting time to CE-CT. 
(ii) PVE technique 
Some argue that in PVE, embolization technique (extending embolization to include segment 
IV) and material (using histoacryl instead of microparticles) can improve the results [80, 81]. 
Here the evidence grade again is poor and based on single centre case series [82]. A head to 
head comparison between PVE and PVL is still lacking. 
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(iii) Tumour progression after PVO 
Also when it comes to risk for tumour progression after PVO result are conflicting. Most 
agree that there is a risk for progression while waiting for the effect of the PVO, but there is a 
variance in risk in the presented studies [83, 84]. When performing PVO in patients with 
CRLM they have in general been subjected to neoadjuvant pre-procedural chemotherapy. 
Some argue that there is a need for chemotherapy after PVE to prevent progression [85, 86], 
others that this risk is small if the time from ending pre-procedural chemotherapy to PVE is 
kept short [87]. One recent study reports a high risk for tumour progression after PVE [88]. 
(iv) Inhibitory factors for hypertrophy after PVO 
Several factors are considered to impair the growth of the FLR after PVO. Among these are 
pre-procedural chemotherapy, high bilirubin levels, concomitant cholangitis and diabetes 
mellitus [76, 89], but the results are still conflicting [90]. 
(v) Alternatives after insufficient effect of PVO 
PVO fails to achieve sufficient growth of the FLR in a considerable amount of patients 
leaving them with no other option than palliative chemotherapy at best [91]. Despite 
additions to PVE, mainly with hepatic vein embolization [92], this fact remains. 
 
2.3 TWO-STAGE HEPATECTOMY 
TSH takes advantage of the regenerative capacity of the liver with tumour clearance of the 
FLR in a first operation. After a waiting time allowing for the FLR to regenerate, a second 
operation with a larger liver resection is performed [93, 94]. TSH has then almost exclusively 
been combined with PVO to induce faster and larger hypertrophy of the FLR [11]. The main 
drawback with TSH (from now together with PVE or PVL) is that a considerable amount of 
patients either experience insufficient growth of the FLR or experience tumour progression 
while waiting for the effect of the PVO [95]. Some argue that this is actually a test of time for 
these patients, in that the time from PVO to CE-CT will offer a better selection of the patients 
that will benefit from surgery by excluding the ones that experience tumour progression while 
waiting [96]. Even if this might be these aspects have been questioned [97], and furthermore 
do not apply to the patients that experience insufficient effect of the PVO without tumour 
progression. Modern chemotherapy has extended median survival for patients with CRLM 
treated with palliative chemotherapy to a median of more than 20 months and five year 
survival in the range of 10% [98, 99], a fact that has to be taken into consideration. Still 
resection is the only curative treatment and for other diagnosis than CRLM chemotherapy 
options are limited or not as beneficial. It is in the light of this that new conversion therapies 
are being received with great interest. 
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2.4 ALPPS 
Associating liver partition and portal vein ligation with staged hepatectomy (ALPPS) was 
first described systematically in a multicentre study from Germany in 2012 [12]. In this study 
25 patients were subjected to a new procedure combining selective right-sided portal vein 
ligation with parenchymal transection between the tumour bearing liver (typically segment 
IV-VIII) and the FLR (segment I-III) in the stage one operation. Following a very fast and 
powerful hypertrophy of the FLR, the second stage was performed after a median of nine 
days where the tumour bearing liver was removed by dividing the right bile duct, liver artery 
and liver vein (the ALPPS procedure is illustrated in Figure 1 below). This retrospective 
analysis included patients from five regional hospitals and consisted of several types of both 
primary and secondary liver tumours. The unprecedented growth rate of the FLR created 
substantial attention from the hepatobiliary surgical community. Together with this attention 
there was also concern about the high morbidity and mortality presented in the study and a 
discussion about the oncological rationale behind this new procedure [96, 100-103]. The 
initial study was immediately followed by several reports of which most contained personal 
communications rather than original articles. To this date almost 200 publications about 
ALPPS can be found in PubMed covering less than 5 years, but only merely 50 of these are 
original articles (when case reports, letters to the editors, reviews, etc. are excluded) being 
mainly small single centre series. 
The original study by Schnitzbauer et al was followed by the experience from other centres, 
reporting a maintained high morbidity and mortality [104-107]. When analysing the patients 
suffering from major complications and mortality after the procedure, there was a clear 
pattern indicating that patients with concomitant biliary surgery were overrepresented. In the 
first publication from the International ALPPS Registry [108] these observations were 
confirmed, and it was also shown that when ALPPS was performed on patients with CRLM 
morbidity and mortality was significantly lower. This has been further investigated and 
confirmed in later publications [97, 109-114]. The proponents of TSH with PVO claimed that 
this strategy remained equally efficient as ALPPS [115, 116] but without taking into account 
that up to 30% of the patients never completed the two stages compared to a completion rate 
of 97-100% with ALPPS [97]. Further criticism was directed towards ALPPS due to 
preliminary reports on early tumour recurrence [117]. In this context it is conceivably not 
appropriate to compare with standard liver resections. ALPPS is probably performed in more 
advance tumour situations where we, prior to the availability of ALPPS, could not offer a 
curative alternative. Consequently patients subjected to palliative chemotherapy might be the 
appropriate group to compare with [118]. However, there is still very limited survival 
analysis following ALPPS so this question remains to be answered. 
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Figure 1. The ALPPS procedure illustrated. 
 
(A) Division of the right portal vein and parenchymal transection, together with eventual 
tumour clearance of the FLR, performed at stage 1. (B) After adequate hypertrophy of the 
FLR, stage 2 is performed with division of right pedicle and liver vein. 
(Modified with permission from Eduardo de Santibañes.) 
 
Considering the high morbidity and mortality associated with ALPPS, many advocate to 
restrain this procedure mainly to patients with CRLM. In addition, there are also proponents 
for the continued use of PVO as the primary method for augmenting FLR size, while 
recognizing ALPPS as a rescue option previously not available for patients with insufficient 
effect on the FLR after PVO [119]. This version of ALPPS, has been named rescue ALPPS 
(where only parenchymal transection is being performed in stage 1 if previous PVO consists 
of PVL). There are a few reports about this procedure, containing only a few patients each, 
where equivalent growth of the FLR as in upfront ALPPS was seen despite previous PVO 
[105, 107, 120-122]. In this context the question arises whether patients with very small FLR 
should be considered for ALPPS upfront. Some patients cannot be expected to experience a 
sufficient effect of PVO considering the more moderate response to this procedure when 
compared to ALPPS. Hence waiting for the effect after PVO when the chance of achieving a 
sufficient effect on FLR is almost non-existing might be an argument in favour of ALPPS 
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upfront. The potent effect ALPPS has on the FLR has even enabled resecting all but one liver 
segment in selected cases [118]. 
The mechanisms behind the potent growth of the FLR that the first stage of ALPPS induces 
are still unknown. However, two theories predominate. One highlights the division of the 
parenchyma that disrupts eventual collaterals between the FLR and the tumour bearing liver, 
thus directing all portal blood to the FLR and thereby facilitating increased hypertrophy 
[123]. This theory has not been investigated in detail and still remains speculative. Another 
theory suggests that the tissue damage caused by the parenchymal transection might release a 
humoral response leading to faster and greater growth of the FLR [25]. Finally studies about 
the function of the FLR after ALPPS are almost completely lacking. The previous studies on 
PVE where function preceded volume increase might not be applicable to the ALPPS setting. 
In conclusion, there is a continued need for studies enabling us to understand the central 
mechanisms behind the clinical effects of both PVO and ALPPS. For both techniques 
improved evaluation of the FLR remains essential. Our ambition with the presented studies is 
that they will contribute to this. 
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3 AIMS 
 
The aims of this thesis were: 
 
Aim I: To evaluate tumour progression after portal vein embolization in patients with 
colorectal liver metastases treated with pre-procedural chemotherapy. 
 
Aim II: To investigate if ALPPS performed after failed portal vein occlusion in patients with 
colorectal liver metastases treated with neoadjuvant chemotherapy is safe, feasible and 
effective. 
 
Aim III: To assess and compare liver volume and function in patients subjected to ALPPS. 
 
Aim IV: To study the levels of liver regenerative growth factors before and after both stages 
of ALPPS and to analyse if the grade of hypertrophy in the future liver remnant is influenced 
by these growth factors. 
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4 METHODS 
4.1 PATIENTS 
In Paper I patients subjected to PVE between 2005 and 2013 at Skåne University Hospital, 
Lund, Sweden, and between 2004 and 2010 at Karolinska University Hospital, Stockholm, 
Sweden, were identified. Of those, patients undergoing a PVE before an intended resection 
for CRLM were identified, including only patients who received chemotherapy within two 
months before PVE, resulting in at least stable tumour situation according to RECIST 1.1 
criteria [124]. 
In Paper II patients with CRLM previously treated with neoadjuvant chemotherapy and 
subjected to PVO but with insufficient effect on the FLR were eligible for the study. A 
FLR/BW of less than 0.5% was considered as an indication for ALPPS after failed PVO [47]. 
In Paper III and IV patients with CRLM that responded to neoadjuvant chemotherapy and 
could be rendered tumour free by an extended right-sided hemihepatectomy (segments IV-
VIII) but where the FLR/BW was below 0.5% were considered for inclusion in the study. 
Patients with previous PVO (PVE or PVL) with insufficient response to the procedure - still 
with a FLR/BW of less than 0.5% - where also considered eligible for inclusion in the study 
if they fulfilled the inclusion criteria stated above. 
 
4.2 EVALUATION OF TUMOUR PROGRESSION AFTER PVE 
In Paper I CE-CT investigations were collected retrospectively and assessed with detailed 
volumetry. The images used for this were the most recent CE-CT prior to initiating pre-
procedural chemotherapy, the most recent scan before PVE (generally the CE-CT for 
evaluating the effect of chemotherapy), and the CE-CT used to evaluate the effect of PVE. 
The liver metastases were considered as bilobar or unilobar depending on their locations. 
Metastases located between both liver lobes were defined as either left or right sided 
depending on where its geometrical centre was located. TFLV was obtained by subtracting 
TV from TLV. FLR was measured as for an intended extended right sided hemihepatectomy, 
meaning that the FLR volume consisted of segments I-III (without eventual tumours in the 
FLR) in all patients. According to the RECIST 1.1 criteria two target lesions were assessed in 
each liver lobe, except in cases of solitary metastases or unilobar manifestation. Tumour 
growth was determined by measuring changes in maximum diameter of the target lesions 
between the analysed scans. Characterization of tumour progression between two CE-CT was 
made for the right and left hemi-liver respectively, and classified as complete response, 
partial response, stable disease or progressive disease. 
In addition, the total volume of all metastases in the right and left lobe, respectively, was 
calculated in the three CE-CT of each patient, by outlining the tumours in each transversal 
image to calculate the area, adding up all calculated areas from the different slides and then 
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multiplying by slide thickness, which was 5 mm or less. As described above, metastases 
located between both liver lobes were defined as either left or right sided depending on where 
its geometrical centre was located, hence the tumour volume of these lesions were assigned to 
only one lobe. Alterations in tumour volume could then be calculated. Analyses were made to 
compare tumour progression between the right and the left lobe, hence comparing tumour 
progression between the embolized and non-embolized liver lobe. Tumour progression in 
right-sided metastases was compared with left-sided metastases within the entire population 
of both patients with bilobar manifestation, as well as those with unilobar metastases. 
 
4.3 PORTAL VEIN OCCLUSION PRIOR TO ALPPS 
PVE was performed with percutaneous ipsilateral technique and puncture of peripheral portal 
branches of the right side. Polyvinyl alcohol beads (Terumo Bead Block™ Embolic Bead, 
Metron Healthcare, Athens, Greece) and polyvinyl alcohol particles (Contour™, Boston 
Scientific, Cork, Ireland) were combined with central coils (MicroNester
®
 Embolization Coil, 
Cook, IN, USA), placed in the right portal vein, to obtain occlusion of the portovenous 
system to segment V-VIII. The portal branches to segment IV were not embolized as this was 
not routine at our centre at the time of the studies. 
PVL was performed by dividing the right portal vein with a stapler instrument (Endo GIA™ 
Universal with Tri-Staple™, Covidien, Dublin, Ireland). PVL was preferred over PVE only 
when the FLR contained metastases and used together with local resections in the FLR at the 
stage 1 operation of an intended conventional TSH. 
 
4.4 SURGICAL STRATEGY AND ASSESSMENT OF COMPLICATIONS 
ALPPS was performed in a similar way as described previously [12]. The patients with failed 
PVE were also subjected to ALPPS with surgical division of the right portal vein (an example 
of rescue ALPPS after failed PVE can be seen in Figure 2 below). In rescue ALPPS after 
failed PVL only parenchymal transection was performed at stage 1 since the right portal vein 
was already divided. If volumetry performed on the CE-CT on day 6 after stage 1 showed 
sufficient hypertrophy of the FLR (resulting in a FLR/BW >0.5%), the stage 2 procedure was 
performed on day 7. At stage 2 the right portal pedicle and right liver vein was divided using 
a stapler instrument and the tumour bearing deportalized liver could be removed as in an 
extended right-sided hemihepatectomy preserving only segment I-III in all patients. In case of 
metastases in the FLR these were resected when possible, or microwave ablated if located 
deep in the FLR. Irrespectively of technique, tumour clearance of the FLR was performed 
during the stage 1 procedure. 
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Figure 2. Exampel of rescue ALPPS after failed portal vein embolization 
 
CE-CT after PVE (A) and CE-CT before stage 2 (B) in the same patient. 
 
Procedure-related complications were assessed according to the Clavien-Dindo classification 
of surgical complications [125, 126]. Evaluation of PHLF was made using the three 
dominating criteria for defining and predicting PHLF: ’50-50 Criteria’, ISGLS Definition and 
peak bilirubin >7 [5, 8, 32]. 
 
4.5 VOLUMETRIC ASSESSMENT IN ALPPS 
Pre-PVO and preoperative FLR volume was calculated from four-phase CE-CT of the liver. 
In Paper II the CE-CT evaluating the effect of the PVO was performed after 28 days in 
median (range 19-33) and was used as baseline investigation. To measure the effect on the 
FLR in ALPPS all patients underwent a new CE-CT of the liver six days after stage 1. In 
Paper III and IV an additional low-dose CT was performed at day 7 and 28 after stage 2 to 
assess the size of the liver remnant. FLR/BW was calculated and TELV was calculated 
according to the previously described formula developed by Vauthey and co-workers to 
obtain sFLR [50]. Percentage FLR increase on day 6 after stage 1 and days 7 and 28 after 
stage 2 examinations were calculated with the preoperative FLR as reference. The kinetic 
growth rate (KGR) of the FLR was calculated separately for the three time intervals (between 
the stage 1 and 2 operations, for the first seven days after stage 2 and for days 8-28 after stage 
2) by dividing the percentage increase of the FLR by the number of elapsed days between the 
examinations, and was then expressed as percentage change per day [115]. All calculations of 
liver volume was performed by using the software Volume Viewer
©
 (Voxtool 11) for AW 
Volume Share 5 implemented on an AW Workstation (GE Healthcare, Fairfield, CT, USA).  
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4.6 EVALUATION OF LIVER FUNCTION IN ALPPS 
4.6.1 Indocyanine green clearance 
Indocyanine green clearance (ICG-C) measured as plasma retention at 15 minutes, expressed 
as percentage (ICG-R15%) was performed at six time points using the LiMON
®
 system 
(PULSION Medical System, Munich, Germany) after intravenous injection of 0.5 mg/kg of 
ICG dye (Verdye
®
, Diagnostic Green GmbH, Aschheim-Dornach, Germany). The time 
points for the ICG-C tests were the day before stage 1 (D-1 OP1), the day after stage 1 (D1 
OP1), the day before stage 2 six days after stage 1 (D6 OP1), the day after stage 2 (D1 OP2), 
seven and 28 days after stage 2 (D7 OP2 and D28 OP2). 
4.6.2 Serum liver function tests 
Prothrombin time measured as the international normalized ratio (INR) and serum bilirubin 
levels were measured daily from the day before stage 1 until day 7 after stage 2 and then 
again on day 28 after stage 2. 
4.6.3 Hepatobiliary scintigraphy 
Hepatobiliary scintigraphy and calculation of functional parameters were performed 
according to a method described previously [70, 127]. Without repositioning the patient a 
low-dose non-contrast-enhanced CT was performed for attenuation correction and anatomical 
mapping. Data were processed on a Hermes workstation (Hermes Medical Solutions AB, 
Stockholm, Sweden). 
Total liver 
99m
Tc-mebrofenin uptake rate (%/min), representing total liver function (TL-
function), was calculated from the dynamic acquisitions as geometric mean. To compensate 
for differences in individual metabolic requirements, TL-function was divided by body 
surface area (BSA) according to the Mosteller formula and expressed as %/min/m
2
. For 
calculation of the FLR-function a region of interest (ROI) delineating the FLR was drawn. 
On the preoperative examination the falciform ligament/umbilical fissure, as visible on 
anterior CT projections was used to delineate the border between segments II/III and IV. On 
day six after stage 1 the FLR was well demarcated by the crevice between segments II/III and 
segment IV facilitating drawing of ROI’s of the FLR as well as the deportalized lobe (DPL) 
for calculation of both FLR-function and DPL-function. Calculation of FLR-function and 
DPL-function was done by dividing the added counts 150-350 seconds after isotope injection 
within the respective delineated ROI’s by the total liver counts within the same time frame 
and multiplying this factor by the total liver 
99m
Tc-mebrofenin uptake rate with values 
expressed as %/min/m
2
. Mebrofenin uptake per litre of FLR tissue was calculated by dividing 
the FLR-function (not corrected for BSA) by FLR-volume and expressed as %/min/l. 
Increase in FLR-function on day 6 after stage 1 and on day 7 and day 28 after stage 2 were 
calculated with the preoperative FLR-function as reference and expressed as percentage 
increase. Kinetic growth rate (KGR) in FLR-function was calculated for the three time 
intervals (between the stage 1 and 2 operations, during the first seven and days 8-28 after 
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stage 2) by dividing the percentage increase for each time period with the number of elapsed 
days and expressed as percentage increase per day. 
 
Figure 3. Hepatobiliary scintigraphy at the four time-points. 
 
HBS with SPECT/CT in a patient with insufficient growth after previous PVE before stage 1 
(A), on day 6 after stage 1 (B), day 7 (C) and day 28 (D) after stage 2. 
 
4.7 TISSUE SAMPLING 
10 ml peripheral blood was collected in an EDTA-coated tube at six time points; the day 
before stage 1 (D-1 OP1), the day after stage 1 (D1 OP1), the day before stage 2 six days 
after stage 1 (D-1 OP2), the day after stage 2 (D1 OP2), day 7 and 28 after stage 2 (D7 OP2 
and D28 OP2). To obtain plasma the blood was centrifuged for 10 minutes at 4000 rounds 
per minute at 4°C (Hettich Zentrifugen Universal 320 R, Hettich Lab Technology, Tuttlingen, 
Germany). Plasma was stored in 2 ml micro tubes (Sarstedt AG & Co, Nürnbrecht, Germany) 
at -80°C until analysed. Biopsies from the left and right liver lobe (segment III and V) where 
taken at both stages of ALPPS using biopsy needle (True-Cut™ Biopsy Needle, CareFusion, 
Sheffield, UK). The biopsies were directly transferred into liquid nitrogen in 2 ml cryogenic 
vials (Corning
®
, Corning Inc, NY, USA) and stored at -80°C until analysed. 
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4.8 QUANTIFICATION OF PLASMA MARKERS AND MRNA 
Plasma levels of epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), 
tumour necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6) were measured in triplicate 
using a Luminex bead-based multiplex assay. Briefly, the assay relies on multi-coloured 
magnetic beads coated with antibodies. Plasma hepatocyte growth factor (HGF) concen-
trations were determined in triplicates with a solid phase sandwich enzyme-linked immune-
sorbent assay (ELISA). Total mRNA was extracted from the liver biopsies using Trizol 
reagent. Quantification of mRNA was performed using real time PCR. All samples were 
analysed in triplicates. Relative mRNA expression was calculated. 
 
4.9 STATISTICAL ANALYSIS 
4.9.1 Paper I 
Statistical analysis was made with SPSS
®
 Statistics, version 21 (IBM, Chicago, IL, USA). 
Median values with range were used for continuous variables whereas frequencies were 
calculated for categorical variables. RECIST classification was compared between groups 
and specifically the percentage of cases that showed progressive disease. Fisher's exact test 
was used to test for statistical significance. The tumour volume change as described above 
was compared between groups using Mann-Whitney U test. Correlation between tumour 
growth rate and time from end of chemotherapy to PVE was calculated using linear 
regression analysis and computing a Pearson correlation coefficient.  P-values of <0.05 were 
considered to represent statistical significance. 
4.9.2 Paper II 
Statistical analysis was made using JMP
®
 version 5.1 (SAS Institute Inc, Cary, North 
Carolina, USA). Median values with range were used for continuous variables whereas 
frequencies were calculated for categorical variables. Paired t-test was used to compare 
means between different time points in the same patient. P-values of <0.05 were considered 
to represent statistical significance. 
Since all variables in the study where presented as median (due to non-normally distributed 
values) it would have been appropriate to use a non-parametric test, instead of the parametric 
paired t-test. However, the statistical tests in the study were controlled (after publication) 
using a non-parametric Wilcoxon signed-rank test, with maintained statistical significance. 
4.9.3 Paper III 
Statistical analysis was performed using SPSS
®
 Statistics, version 23 (IBM, Chicago, Illinois, 
USA) and GraphPad Prism
®
, version 7 (GraphPad Software, La Jolla, California, USA). 
Median values with range were used for continuous variables whereas frequencies were 
calculated for categorical variables. The Wilcoxon signed-rank test was used to compare 
differences in liver volume and function and the Spearman’s rank correlation coefficient was 
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used to test for correlation between volumetric and functional parameters. Two-tailed P-
values of <0.05 were considered to represent statistical significance. 
4.9.4 Paper IV 
Statistical analysis was performed using SPSS
®
 Statistics, version 23 (IBM, Chicago, IL, 
USA) and GraphPad Prism
®
, version 7 (GraphPad Software, La Jolla, CA, USA). Continuous 
variables were expressed as median with range or inter-quartile range (IQR), whereas 
frequencies were calculated for categorical variables. Wilcoxon’s signed rank test was used to 
compare differences in liver volume at different time-points, for comparison of growth 
factors between baseline and the different time-points and for mRNA expression between 
stage 1 and 2 of ALPPS. Correlations were evaluated with linear regression and Spearman’s 
rank correlation. A two-tailed p-value of <0.05 was considered to represent statistical 
significance. 
 
4.10 ETHICAL CONSIDERATIONS 
The first study was approved by the Regional Ethical Review Board in Lund and in 
Stockholm, Sweden. Since this study was purely retrospective in nature, informed consent 
from the included patients was not required by the Regional Ethical Review Boards. 
Studies two, three and four were approved by the Regional Ethical Review Board, 
Stockholm, Sweden. For study three approval was also granted from the Radiation Safety 
Committee at Karolinska University Hospital, Stockholm, Sweden. Since these studies were 
designed in a prospective manner written and oral informed consent was obtained from each 
patient before inclusion and the study protocol confirmed with the ethical guidelines of the 
1975 Declaration of Helsinki. 
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5 RESULTS AND DISCUSSION 
5.1 AIM I: ASSESSING TUMOUR PROGRESSION AFTER PVE 
In Paper I a total of 34 patients with CRLM treated with chemotherapy and then right-sided 
PVE for an intended curative resection were included in the study. 23 patients had bilobar 
liver metastases. All patients had response to chemotherapy prior to PVE with a median of 
seven administrated cycles. Of the 34 included patients, 17 were subjected to an extended 
right-sided hemihepatectomy and nine to a right-sided hemihepatectomy. Eight patients were 
not resected due to extrahepatic tumour progress (n=3), insufficient growth of the FLR after 
PVE (n=3), pronounced progress of metastases in both liver lobes (n=1) and one new 
unresectable metastasis detected intra-operatively in the FLR (n=1). 
Tumour progress in the right lobe was analysed for all patients (n=34) and tumour progress in 
the left lobe was analysed in patients with bilobar disease (n=23). There was no difference in 
tumour growth between the embolized and non-embolized liver lobe after PVE. There was a 
linear correlation between the volumetric tumour growth and time between end of chemo-
therapy and PVE (r=0.25, p<0.001).  
In three patients progressive tumour growth was noted after PVE in both the embolized and 
non-embolized liver lobe, representing 3/34 and 3/23 of cases, respectively (p=0.677). 
In this study we demonstrated a lower probability of progressive tumour situation after PVE 
compared to previous reports. Tumour response after PVE has been investigated previously 
to a limited extent and only one study [85] has evaluated tumour response after PVE 
according to RECIST criteria. In that study, Fischer et al reported a tumour progression rate 
of 34% after PVE. However, in the mentioned study, no details are stated about chemo-
therapy before PVE, making it difficult to compare these results. 
With measurement of tumour volume we could demonstrate a decrease in tumour volume 
after PVE in both liver lobes (16% in right-sided tumours and of 11% in left-sided tumours), 
which is less than in previous studies. In a study by Simoneau et al [128] consisting of a large 
cohort of patients treated with chemotherapy and then subjected to PVE, a significant tumour 
growth after PVE was found. However, in the mentioned study the interval from the cessation 
of chemotherapy to PVE was 4 weeks compared to 16 days in our study. In another study by 
Pamecha et al [86] an increase in tumour diameter after PVE was reported. All patients in this 
study received pre-PVE chemotherapy, but details about chemotherapy response or time 
between the cessation of chemotherapy and PVE was not stated, making comparison between 
that study and ours difficult. 
We are not the first ones to report tumour regression after chemotherapy and subsequent 
PVE. In a study by Pommier et al [129] tumour shrinkage of 4% in the right lobe and 9% in 
the left lobe was reported in patients with a ‘fast response’ to chemotherapy before PVE. In 
that study, the time between ending chemotherapy and PVE was also longer compared to our 
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study, again giving a possible explanation to the differences between the studies. The present 
study showed that tumour growth increases the longer the time elapsed between end of 
chemotherapy and PVE. 
Chemotherapy prior to PVE has been suggested to reduce the effect of the procedure on the 
hypertrophy of the FLR. Prolonged pre-PVE chemotherapy has been associated with reduced 
hypertrophy in the non-embolized lobe [89, 130], but other studies have failed to show any 
influence of chemotherapy on regeneration [131, 132]. In the present study of right-sided 
PVE, the median FLR increased from 19% to 29%, which is similar, although somewhat 
lower, to what has been reported in previous studies [89, 132]. 
The results of the present study suggest that tumour growth in the right and left liver lobe 
after PVE is comparable. This is in accordance with two previous studies investigating the 
subject [85, 129]. 
 
5.2 AIM II: THE VALUE OF RESCUE ALPPS AFTER FAILED PVO 
In Paper II eleven patients with CRLM responsive to neoadjuvant chemotherapy and then a 
PVO with insufficient effect (FLR/BW still below 0.5%) were included and submitted to 
ALPPS. The patients had a median of seven cycles of chemotherapy prior to PVO. Six days 
after stage 1, FLR was evaluated with CE-CT and stage 2 was performed on day 7. All 
patients had metastases located in both liver lobes (in the right lobe and in segment IV), but 
only four had metastases in segments I-III requiring tumour clearance in the FLR at the first 
stage of the ALPPS procedure. All patients completed stage 2 with radical (R0) removal of 
all metastases together with the deportalized liver (segments IV-VIII). The complication rate 
was low. Four patients had grade 3a-complications due to pleural effusion that was drained in 
local anaesthesia. There were no complications equal to or above grade 3b. Postoperatively 
no patient fulfilled the ’50-50 Criteria’, peak bilirubin >7 or ISGLS grade C for severe 
postoperative liver failure and no 90-day mortality occurred. 
FLR volume before PVO was 250 ml (range 180-370). After PVO the FLR increased to 312 
ml (range 260-450), representing a PVO induced hypertrophy of the FLR of 26.8% (range -
7.3-66.7, p=0.006). Despite previous PVO there was an adequate hypertrophy of the FLR 
after the ALPPS stage 1 procedure. Six days after stage 1 the median volume increase of the 
FLR was 209 ml (range 87-314, p <0.001). This corresponded to an increase of FLR/BW to 
0.69% (range 0.59-0.81), i.e. more than 0.5% in all patients (see Figure 4). The growth of the 
FLR between stage 1 and 2 was in median 61.8% (range 19.3 – 120). 
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Figure 4. Increase in future liver remnant to body weight ratio. 
 
Box-whisker plot displaying the increase in FLR/BW between stage 1 and 2 of ALPPS in 
patients subjected to rescue ALPPS. Dotted red line shows 0.5%. 
 
This study confirms results from previous reports that ALPPS can be safe, feasible and 
effective as a rescue procedure in patients with CRLM and insufficient effect on the FLR 
after previous PVO. In addition it seems as if the described high morbidity and mortality 
associated with ALPPS does not apply when performing the procedure in this clinical setting. 
Despite the limited number of patients enrolled, the patient cohort of this study still represents 
the largest series of rescue ALPPS for CRLM so far presented. The main aim of this study 
was, however, to specifically investigate the safety, feasibility and efficacy of rescue ALPPS 
in this clinical situation. The studied patients represent a comparatively homogenous cohort 
in that they all received chemotherapy for CRLM only, they were all subjected to PVO prior 
to ALPPS and they were all operated with an extended right-sided hemihepatectomy on the 
seventh day after stage 1 operation. 
In the current study cohort the overall median growth of the FLR before stage 2 was 61.8%, 
which is less than reported in most previous studies. This might, however, be explained by 
two factors. Firstly, in contrast to many other reports on ALPPS, only patients with CRLM 
treated with pre-procedural chemotherapy were included. It is recognized that pre-PVE 
chemotherapy can have a negative effect on growth of the FLR after PVE [89, 133] and it 
might have the same effect after ALPPS, although this remains to be proven. Another 
complicating factor was that the interval between the cessation of chemotherapy and ALPPS 
was quite long due to the waiting time from PVO to ALPPS. Consequently the alleged 
negative effect of pre-procedural chemotherapy on FLR hypertrophy might have been less 
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pronounced in these patients compared to the patients undergoing ALPPS without previous 
PVO. Secondly, the inter-stage time of seven days used for all patients in this study was 
shorter than in most published series [111].  That might in part explain the somewhat less 
pronounced hypertrophy rate. On the other hand, the growth of the FLR of 61.8% in six days 
represents a kinetic growth rate of 10.3%/day which is higher than for example in the 
publication by Schnitzbauer et al [12] (74% increase in nine days = 8.2%/day). Of course, 
these calculations are based on the assumption that the present patients would have had a 
continued similar growth rate beyond the sixth day. Nevertheless, previous PVO does not 
seem to significantly impair the potent hypertrophic effect on the FLR induced by the stage 1 
procedure in ALPPS.  
 
5.3 AIM III: FLR VOLUME VS FUNCTION AFTER ALPPS 
In Paper III nine patients with CRLM were included into the study. All patients received 
neoadjuvant chemotherapy comprising a median of six cycles (range 4-14). In five patients 
the liver metastases were detected synchronously to the primary tumour and two patients had 
tumour manifestation in the FLR in addition to the right liver lobe and segment IV. Six 
patients had previous failed PVO (PVE 3; PVL 2; PVL and PVE 1) prior to inclusion, 
meaning that PVO did not induce sufficient growth of the FLR with a FLR/BW still below 
0.5% after evaluation of the PVO effect. The stage 2 operation was performed in all patients 
seven days after the stage 1 operation. 
All patients completed the stage 2 operation with removal of segments IV-VIII. Pathological 
examination showed radical resection (R0) in seven patients while two patients had tumour 
cells within 1 mm of the resection line (R1). One patient with bile leakage after stage 2 
required endoscopic stenting under general anaesthesia thus denoted as a grade 3b-
complication. Three patients had pleural effusions requiring drainage under local anaesthetic 
(grade 3a-complication). No patient developed severe posthepatectomy liver failure (PHLF) 
and there was no 90-day mortality. 
The median ICG-R15 on the day before stage 1 operation was 9.9% (range 1.2-20.7) and on 
day 6 after stage 1 7.0% (4.2-19.5). There was a significant rise in ICG-R15 directly after 
stage 2 (33.3%, 8.5-43.2, p=0.012) that was maintained on day 7 after stage 2 (28.8%, 19.2-
38.9) and on day 28 after stage 2 (22.2%, 10.3-37.5). 
 
 
 
 
 
  23 
Figure 5. Dynamic evaluation of ICG clearance in ALPPS. 
 
Indocyanine green retention at 15 minutes (ICG-R15%) at six time points before and after 
both stages of the ALPPS procedure. *p<0.05, **p<0.01. 
 
The median preoperative FLR-volume was 300 ml (range 260-433) translating into a median 
sFLR of 19.5% (16.1-25.8). On day 6 after stage 1 and days 7 and 28 after stage 2 the FLR-
volume had increased to 557, 700 and 793 ml respectively (p=0.008, 0.011 and 0.008), 
translating into a median sFLR of 33.1, 40.6 and 48.0%. The median FLR-volume percentage 
increase on day 6 after stage 1, day 7 and day 28 after stage 2 were 56.7% (range 32.3-110.4), 
114.7% (48.8-174.3) and 132% (90-218.3) using the preoperative FLR-volume and TELV as 
references. Median FLR/BW before stage 1 was 0.41% (range 0.35-0.49) and increased to 
0.71% (0.54-0.90, p=0.008) prior to stage 2. The median KGR of the FLR-volume was 
9.4%/day (range 5.4-18.4) during the six days between stage 1 and 2, 3.8%/day (-0.3-8.2) 
during the first seven days after stage 2 and 0.5%/day (0.1-4.2) from day 8 to 28 after stage 2 
(volumetric data of the FLR are summarized in Figure 6a). 
The median preoperative FLR-function was 1.8%/min/m
2
 (range 1.4-2.9), translating into a 
median FLR-function/TL-function share of 25.3% (19.3-33.1). On day 6 after stage 1 and 
days 7 and 28 after stage 2 the median FLR-function had increased to 2.6, 3.4 and 
4.1%/min/m
2
 respectively (p=0.051, 0.036 and 0.011), resulting in FLR-function/TL-function 
shares of 33.9, 43.7 and 55.5%. Using the preoperative FLR-function and TL-function share 
as reference the median FLR-function increase on day 6 after stage 1, day 7 and day 28 after 
stage 2 were 28.2% (range -35.7-83.8), 66.4% (0.7-147.5) and 92.2% (47.3-191.5) 
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respectively. It was notable that the median FLR uptake rate per volume unit was decreased 
significantly on day six after stage 1 (8.5%/min/l) compared to preoperatively (11.8%/min/l, 
p=0.028), and did not surpass the preoperative values on day 7 (9.0%/min/l) or on 28 after 
stage 2 (10.1%/min/l). The median KGR of the FLR-function was 4.7%/day (range -6-14) 
during the six days between stage 1 and 2. During the seven days following stage 2 it was 
4.9%/day (range -2-24.9) and from day 8 to 28 after stage 2 it decreased to 1.4%/day (-0.3-
2.2) (functional data of the FLR are summarized in Figure 6b). 
 
Figure 6. (A) FLR-volume (ml) compared to kinetic growth rate (KGR) of volume increase 
(%/day) at the four time points; pre stage 1, day 6 after stage 1, day 7 and 28 after stage 2. 
(B) FLR-function (%/min/m
2
) compared to KGR of function increase (%/day) at the same 
time points. 
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The preoperative sFLR of 19.5% underestimated the preoperative FLR-function/TL-function 
share of 25.3% (p=0.011). The median increase in volume exceeded the increase in function 
at day six after stage 1 (FLR-volume increase 56.7% versus FLR-function increase 28.2%, 
p=0.021). The increase in volume still exceeded increase in function the first seven days after 
stage 2 (FLR-volume increase 114.7% versus FLR-function increase 66.4%, p=0.028) but 
with greater functional growth rate after stage 2 resulted in comparable levels on day 28 
(FLR-volume increase 132.0% versus FLR-function increase 92.2%, p=0.11), with the 
preoperative FLR-volume and FLR-function as reference. 
 
Figure 7. Volume versus Function. 
 
Comparison of percentage increase in FLR-volume (FLR-V) and FLR-function (FLR-F) day 
6 after stage 1 and days 7 and 28 after stage 2, with preoperative FLR-V and FLR-F as 
reference. 
 
The ALPPS procedure has been suggested as an alternative to PVO for inducing hypertrophy 
of the FLR [12]. Proponents claim a more rapid increase in FLR as compared to the 
traditional methods for FLR manipulation [111]. Resection rates for patients with CRLM 
after ALPPS of 97-100% have been reported, compared to around 70-80% after PVO [111]. 
Tumour recurrence rates at 1-year follow-up for ALPPS and PVO were comparable [97]. 
Sceptics have raised concern that the extreme increase in FLR size is not necessarily the 
 26 
result of true hypertrophy [100]. Furthermore the relationship between hypertrophy and 
increased function has been questioned [134, 135]. 
In the present study a 56.7% median increase in FLR-volume was paired with a 28.2% FLR-
function increase day 6 after stage 1, or in other words the functional increase represented 
only 50% of the increase in volume. This gives some legitimacy to fears that the fast initial 
growth in volume after ALPPS does not translate into an equivalent increase in function. This 
may, in part, explain the observation that extreme hypertrophy does not necessarily ensure a 
sufficient FLR and safe postoperative course [107]. 
In a letter to the editor, Lau et al presented a case report implying the use of repeated ICG 
measurement for resectability decision-making in ALPPS [136]. In the present study ICG 
values did not increase directly after stage 1 or prior to stage 2. The pronounced increase in 
ICG seen from day 1 after stage 2 did not translate into liver failure, and might simply be a 
result of increased blood flow to the liver remnant after resecting the DPL. Whether a sharp 
increase in ICG prior to stage 2 could indicate a need to postpone stage 2 operation remains 
to be investigated in larger cohorts of patients. 
 
5.4 AIM IV: CHARACTERIZATION OF GROWTH FACTORS IN ALPPS 
In Paper IV ten patients with CRLM were included into the study. All patients received 
neoadjuvant chemotherapy containing a median of six cycles. Seven patients had failed PVO 
(PVE 4; PVL 2; PVL and PVE 1) before inclusion, meaning that PVO did not induce 
sufficient growth of the FLR with a FLR/BW still below 0.5% after evaluation of the PVO 
effect. 
The preoperative FLR was 342 ml (range 260-433) translating into a FLR/BW of 0.41% and 
a sFLR of 19.7%. On day 6 after stage 1 the FLR had increased significantly to 562 ml 
(p<0.001), resulting in a FLR/BW of 0.64% and a sFLR of 30.6%. The median FLR 
percentage increase on day 6 after stage 1 was 55.7% (32-120). KGR of the FLR was 
9.3%/day (5.4-20) during the six days between stage 1 and 2. The hypertrophy of the liver 
remnant slowed down after stage 2 but the increase was still significant at day 7 and 28 
(p=0.01 and 0.004 respectively). The liver remnant accounted for 41.7% of the TELV seven 
days after stage 2 and 48% 28 days after stage 2; meaning that the liver remnant four weeks 
after completed ALPPS still did not reach half the preoperative TELV. 
Plasma levels of IL-6 increased at D1 OP1 (p=0.004) compared to baseline. The 
concentration then declined but was still higher compared to baseline at D-1 OP2 (p=0.002), 
D1 OP2 (p=0.004) and D7 OP2 (p=0.008). Plasma EGF decreased compared to baseline at 
D1 OP1 (p=0.004) and was lower also at D-1 OP2 (p=0.01), D1 OP2 (p=0.004) and D7 OP2 
(p=0.015). TNF-alpha declined at D1 OP1 compared to baseline (p=0.02). There was no 
difference compared to baseline at D-1 OP2 (p=0.65), but was significantly lower at D-1 OP2 
(p=0.045) and at D7 OP2 (p=0.04) compared to baseline. VEGF was lower at D1 OP1 
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(p=0.01) compared to baseline. Because of inter-individual variations in the time-point for the 
peak concentration of the evaluated factors in combination with a limited sample size, the 
differences between baseline concentrations and peak concentrations of each factor were 
assessed. There was a significant change in plasma levels between baseline and peak for IL-
6, HGF and VEGF (p=0.02, p=0.048 and p=0.048, respectively). 
To evaluate the relation between plasma markers for liver regeneration and growth of FLR, 
regression analysis was performed. There was a strong correlation between peak plasma 
concentrations of IL-6 and HGF (R
2
=0.83, p=0.03). Furthermore, HGF correlated to the 
growth of FLR at D-1 OP2 (R
2
=0.47, p=0.02), though the growth did not correlate to IL-6 
(R
2
=0.20, p=0.57). 
 
Figure 8. Peak levels of HGF correlates to peak levels of IL-6 and growth of FLR. 
 
Correlation between (A) peak levels of HGF and IL-6, (B) peak levels of HGF and growth of 
FLR between baseline and D-1 OP2, (C) peak levels of IL-6 and growth of FLR between 
baseline and D-1 OP2 (n=10). 
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Expression of Ki67 and PCNA (proliferating cell nuclear antigen) increased in both lobes at 
stage 2 compared to stage 1. The increase was more prominent in the right lobe compared to 
the left lobe (right lobe; p=0.03 and p=0.05, left lobe; p=0.12 and p=0.69). 
 
Figure 9 Ki67 and PCNA mRNA expression in ALPPS. 
 
Ki67 (A) and PCNA (B) mRNA expression increases significantly in the right lobe, but not the 
left, between stage 1 and 2. 
 
IL-6 has been suggested to stimulate the production of HGF in liver regeneration [137, 138] 
which is consistent with the results of the present study, in that high levels of IL-6 directly 
after stage 1 correlated with high HGF levels. Furthermore, high levels of HGF correlated 
with a greater growth of the FLR. The rapid increase in IL-6 is similar to that described by 
Sasturkar et al [22] but in that study in healthy donors peak levels of HGF were detected later 
than in the present study. In the study by Matsumoto et al [21], also in healthy donors, HGF 
peaked early after partial hepatectomy as reported in the present study. In addition, a late 
expression of VEGF was seen, similar to what is shown in this study. 
Several attempts to study proliferation in ALPPS [27, 139] have shown increased 
proliferative markers in the FLR. One advantage with the current study is that the 
deportalized liver was used as internal control in that bilobar biopsies at both operations were 
compared in all patients. Although a trend towards elevation in mRNA expression of both Ki-
67 and PCNA was seen in the FLR between both stages, there was a greater increase in the 
deportalized lobe. This appears to be a paradox, but it might represent a response to apoptosis 
in the hypoxic liver. Schadde et al recently described that tissue hypoxia in the FLR after 
ALPPS lead to a higher degree of regeneration [140]. 
Another interesting finding is that the initial fast and powerful hypertrophy after stage 1, 
slowed down significantly after stage 2. In fact, 28 days after stage 2 the liver remnant still 
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did not reach half the initial size of the liver and with a much lower KGR than in other 
settings [141]. 
The present study is the first to describe serial measurements of multiple growth factors in 
plasma in humans subjected to ALPPS and correlate these levels with a detailed volumetric 
study after both stages of the procedure. In addition, this study present an analysis of mRNA 
expression of proliferative and apoptotic markers in both liver lobes at both stages of ALPPS. 
 
5.5 GENERAL DISCUSSION AND CLINICAL IMPLICATIONS 
A general limitation for all the papers in this thesis is the limited number of included patients 
in each study. This is a common problem for most studies in the field of PVO and ALPPS. 
Still, for several results in this thesis, other recent studies report similar conclusions. Until 
more solid evidence is presented, interpretation of these results always has to be undertaken 
with this limitation in mind. Another concern regards the selection of patients for the studies. 
In particular, when analysing only rescue ALPPS patients there is an obvious built-in 
selection bias. Patients previously subjected to PVO that either have a satisfactory growth of 
the FLR or experience tumour progression after PVO excluding them from curative surgery, 
are not analysed in the mentioned setup. 
Recent attempts to compare early survival after ALPPS with two-stage hepatectomy [142] or 
even palliative chemotherapy [143] for patients with advanced liver metastatic disease from 
colorectal cancer indicate poor results for ALPPS, not even being superior to palliative 
chemotherapy. This is of course concerning, but several objections could be raised on the 
methodology in the studies, making generalisation of the results premature. Despite that, an 
important conclusion is that patient selection in ALPPS is pivotal and that further studies are 
warranted. 
If the results from Paper I could be confirmed in larger studies it would have the potential to 
change our current approach when planning surgical strategy for patients with colorectal liver 
metastases in the FLR. Instead of TSH these patients could be managed with percutaneous 
PVE shortly after ended chemotherapy and a subsequent one-stage operation with complete 
resection of all tumours.  
In Paper II we confirmed the results from previous reports, that the pronounced growth of 
FLR associated with ALPPS, is maintained after rescue ALPPS despite of previous PVO in 
this setting. There are also indications that both volume and function increase of the FLR 
after PVE is faster than currently estimated [69, 144]. If this is confirmed it could change the 
way we use PVE and also lay the foundations for a new strategy in dealing with a small FLR. 
This potential strategy would comprise preference to use PVE in small FLR with earlier 
evaluation of the PVE effect, and then rescue ALPPS taking advantage of the second growth 
of the FLR. Of course this treatment strategy would have to be confirmed scientifically before 
a broader implementation can be recommended.  
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The need for an accurate tool for functional assessment of the FLR, in particular in ALPPS, is 
gaining attention in the hepatobiliary community. The described morbidity and mortality 
associated with ALPPS (mainly due to PHLF despite adequate FLR volumes prior to stage 
2), together with the results from Paper III, have altered the management of ALPPS patients 
at Karolinska University Hospital. Our current strategy is to supplement the volume 
measurement of the FLR (based on CE-CT before stage 1 and seven days after stage 1, i.e. 
the day before stage 2) with HBS and ICG clearance test before both stages of ALPPS. If we 
observe a satisfactory increase in FLR-volume before stage 2, but the ICG-value are 
significantly increased or HBS indicate a poor FLR-function, the stage 2 procedure is 
postponed. 
Paper IV lack obvious clinical implications because of its descriptive nature, but could 
engage in more translational studies for enhanced understanding of liver regeneration in 
general. 
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6 CONCLUSIONS 
 
This thesis provides results to support the following conclusions: 
 
The rate of progression of CRLM after PVE and pre-procedural chemotherapy is lower than 
previously reported if the time between the end of chemotherapy and PVE is short. 
 
The risk of tumour progression is low both in the embolized and non-embolized liver. 
 
The powerful growth of the FLR associated with ALPPS seems to be maintained in patients 
with CRLM treated with neoadjuvant chemotherapy and previously failed PVO. 
 
In patients with CRLM treated with neoadjuvant chemotherapy and previously failed PVO, 
ALPPS can be performed with low morbidity and high resection rate. 
 
During the inter-stage period of ALPPS the high volume increase is not paralleled by a 
corresponding functional increase. 
 
The demonstrated discrepancy between volume and function in the FLR prior to stage 2 
warrants additional functional assessment before proceeding to stage 2. 
 
IL-6, HGF and TNF-α seem to be early mediators of hypertrophy after stage 1 in the ALPPS 
procedure, whereas EGF and VEGF seem to increase later. 
 
The levels of HGF correlates significantly with the degree of growth of the FLR in patients 
subjected to ALPPS. 
 
The levels of IL-6 correlates significantly with the levels of HGF in patients subjected to 
ALPPS. 
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7 FUTURE RESEARCH 
 
There is a remaining need to investigate the issues in this thesis further.  
The volumetric assessment of the liver in connection with both portal vein occlusion and liver 
resection are being explored in several projects that we have initiated, both locally and 
together with other hepatobiliary centres in Sweden. 
Recently the first randomized controlled study comparing portal vein occlusion and ALPPS 
completed the enrolment of patients (actually the first RCT in ALPPS). It is a Nordic multi-
centre study and we are one of the contributing centres. Data analysis is being performed and 
the presentation of the results from the study will be of great importance in regard to the 
future use of these procedures. 
The network of the participants from the first international expert meeting in ALPPS held in 
Hamburg in 2015 created a platform for research collaborations. Recently an international 
multi-centre study pooling all hepatobiliary scintigraphies in ALPPS from four participating 
centres (including Stockholm) was performed. An additional initiative was recently conveyed 
by the coordinator of the International ALPPS Registry with the aim of collecting all patients 
subjected to ALPPS with HBS for evaluation of FLR function in a world-wide setting. 
Hopefully this can lead to increased knowledge of this promising method for assessment of 
the functional FLR and potentially contribute to a decreased occurrence of posthepatectomy 
liver failure after ALPPS. 
Since portal vein occlusion and ALPPS are used to avoid posthepatectomy liver failure 
further studies, taking advantage of the interface between these research fields, will be 
received with great interest. 
The ALPPS procedure has generated significant interest as a promising model to study liver 
regeneration in humans. This creates a favourable foundation for translational studies that 
could contribute to a deepened understanding of the complex mechanisms behind liver 
regeneration. 
In summary, for me the work with this thesis has created a base for future research with the 
translational, national and international projects being especially rewarding. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Vid tumörer i levern kan kirurgisk behandling erbjuda bot för patienten. En förutsättning 
för att leverkirurgi med botande syfte ska kunna utföras är att patienten har tillräckligt stor 
kvarvarande lever efter operationen. Om den kvarvarande levern efter operation är för liten 
löper patienten stor risk att utveckla postoperativ leversvikt, vilket är den allvarligaste 
komplikationen till leverkirurgi. Därför använder man röntgen för att mäta volymen på den 
friska delen av levern innan man opererar patienten. Ett problem med denna volyms-
baserade beslutsgrund inför leverkirurgi är att den inte tar tillräcklig hänsyn till kvalitet och 
funktion i den delen av levern som patienten har kvar efter operation. Det gör att vissa 
patienter utvecklar postoperativ leversvikt trots att volymen på den kvarvarande levern 
ansågs vara tillräcklig innan kirurgi. Ett annat problem är när volymen på den friska, icke 
tumörbärande delen av levern är för liten. Dessa patienter har tidigare blivit exkluderade 
från potentiellt botande kirurgi på grund av den stora risken för postoperativ leversvikt. 
En metod som kan användas för att skapa tillväxt i den friska delen av levern är selektiv 
portavensavstängning av portavenen till den sjuka delen av levern. Portavenen är det 
blodkärl som transporterar den näring som tas upp från tarmen till levern. Principen bakom 
portavensavstängning är att styra det näringsrika portablodet till den friska delen av levern 
för att få denna del att bli större innan leverkirurgi. Portavensavstängning kan antingen 
utföras med hjälp av röntgen - det kallas då portavensembolisering - eller med en kirurgisk 
delning av portavenen till den sjuka delen av levern. Om denna metod är framgångsrik 
skapar den tillräckligt stor tillväxt av den friska delen av levern så att levertumörerna några 
veckor senare kan opereras bort utan stor risk för postoperativ leversvikt. Även om en stor 
del av patienterna når målet med denna metod är det cirka 20-30 % som antingen inte får 
tillräckligt stor tillväxt eller att tumörerna växer för mycket i väntan på effekten av 
portavensavstängningen. Dessa patienter har tidigare inte kunnat erbjudas botande 
behandling. 
En ny kirurgisk metod som kallas ALPPS (associating liver partition and portal vein 
ligation for staged hepatectomy) har sedan den presenterades 2012 visat sig vara mycket 
effektiv när det gäller att skapa snabb och kraftfull tillväxt av den friska delen av levern. 
Det är en tvåstegsoperation där man vid första operationen delar portavenen till den 
tumörbärande delen av levern (precis som vid kirurgisk portavensdelning) och samtidigt 
klyver man levern mellan den sjuka och friska delen. Efter att man utfört en ny röntgen 
cirka sju dagar efter första operationen och sett att den friska levern växt tillräckligt mycket, 
genomförs den andra operationen där man avlägsnar den tumörbärande delen av levern. I 
Figure 1 på sidan 7 har metoden illustrerats. De första rapporterna om denna metod visade 
att den friska levern växte så pass mycket att nästan samtliga patienter (97-100 %) kunde 
genomgå även den andra operationen och bli av med sina levertumörer. Dock höjdes ett 
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varnande finger för att metoden var förknippad med större komplikationsrisk och även 
högre dödlighet till följd av operationen, jämfört med annan leverkirurgi. 
Det aktuella avhandlingsarbetet studerade ovanstående tekniker i fyra delarbeten. 
I delarbete I inkluderades 34 patienter med tjock- och ändtarmscancer som utvecklat 
dottertumörer i levern och behandlats vid Skånes Universitetssjukhus och Karolinska 
Universitetssjukhuset. Samtliga patienter i studien hade för liten kvarvarande lever för att 
kunna opereras i levern direkt och behandlades därför med portavensembolisering. Innan 
portavensemboliseringen hade patienterna fått förbehandling med cellgifter. Syftet med 
studien var att undersöka om dottermetastaserna i levern växte i väntan på effekten av 
portavensemboliseringen. Det viktigaste resultatet av studien var att om tiden mellan 
avslutad cellgiftsbehandling och portavensembolisering hålls kort, så är risken för oönskad 
tillväxt av dottertumörerna låg. 
I delarbete II undersöktes om ALPPS kan användas efter misslyckad portavensavstängning 
som ett sista försök att bota patienten. Studien inkluderade elva patienter med tjock- och 
ändtarmscancer som utvecklat dottertumörer i levern och genomgått portavensavstängning 
utan tillräcklig tillväxt av den friska levern. För det första sågs en liknande tillväxt som vid 
de första rapporterna om ALPPS, trots att dessa patienter tidigare genomgått portaven-
savstängning. För det andra kunde samtliga patienter genomgå även den andra operationen 
och bli av med sina levertumörer utan hög komplikationsfrekvens och helt utan dödlighet 
till följd av ingreppet. 
I delarbete III studerades leverns tillväxt och funktion i samband med ALPPS med hjälp av 
flera olika metoder (skiktröntgen, gammakamera, indocyaningrönt leverfunktionstest och 
blodprover). Studien inkluderade nio patienter med tjock- och ändtarmscancer som 
utvecklat dottertumörer i levern och som opererades med ALPPS. Resultaten visar att den 
kraftiga volymstillväxten av den friska levern efter första operationen i ALPPS inte åtföljs 
av en lika stor funktionell ökning. Detta skulle kunna förklara den höga frekvens leversvikt 
som beskrivits efter andra operationen i ALPPS, trots att adekvat volymstillväxt uppmätts. 
I delarbete IV studerades nivåerna av tillväxtfaktorer med betydelse för levertillväxt i 
vävnad hos tio patienter som genomgått ALPPS. Upprepad blodprovstagning utfördes före 
och efter båda operationerna i ALPPS. Vidare togs vävnadsprov från levern vid båda 
operationerna. Dessa vävnadsprover analyserades sedan för ett antal tillväxtfaktorer och 
jämfördes med tillväxtgraden i den friska levern. Studien har för första gången gett oss en 
bild av uttrycket av dessa tillväxtfaktorer efter utförd ALPPS hos människa. 
Sammanfattningsvis har studierna i denna avhandling bidragit till att öka förståelsen för 
vissa aspekter vid portavensavstängning och ALPPS. 
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